A Dose-escalation Phase I Trial of PD-1 Knockout Engineered T Cells for the Treatment of Castration Resistant Prostate Cancer is a registry-stage clinical asset sponsored by Peking University in Hormone Refractory Prostate Cancer. SEO and diligence focus: PD-1 Knockout T Cells, Cyclophosphamide, IL-2, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.